Gyre Therapeutics (GYRE) Non-Current Assets (2010 - 2026)
Gyre Therapeutics (GYRE) reported Non-Current Assets of $70.3 million for Q1 2026, up 14.58% year-over-year from $61.3 million in Q1 2025, and up 10.23% on a QoQ basis from $63.8 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Non-Current Assets data on file, last reported at $70.3 million in Q1 2026.
- Quarterly Non-Current Assets rose 14.58% year-over-year to $70.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $256.2 million (down 1.38% YoY) and the FY2025 annual result came in at $63.8 million, up 5.18% from the prior year.
- Non-Current Assets rose to $70.3 million in Q1 2026 per GYRE's latest filing, from $63.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $70.4 million in Q3 2024 and bottomed at $773000.0 in Q3 2022.
- The 5-year median for Non-Current Assets is $59.3 million (2023), against an average of $40.6 million.
- The widest annual swing landed in 2022, when Non-Current Assets slumped 83.1%; it then surged 1357.6% in 2024.
- Tracing GYRE's Non-Current Assets over 5 years: stood at $35.1 million in 2022, then surged by 69.0% to $59.3 million in 2023, then climbed by 2.19% to $60.6 million in 2024, then rose by 5.18% to $63.8 million in 2025, then rose by 10.23% to $70.3 million in 2026.
- Per Business Quant, the three latest GYRE Non-Current Assets figures stand at $70.3 million (Q1 2026), $63.8 million (Q4 2025), and $60.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 70.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.28 Mn |
| Dec 31, 2025 | 63.76 Mn |
| Sep 30, 2025 | 60.81 Mn |
| Jun 30, 2025 | 61.36 Mn |
| Mar 31, 2025 | 61.34 Mn |
| Dec 31, 2024 | 60.62 Mn |
| Sep 30, 2024 | 70.43 Mn |
| Jun 30, 2024 | 67.41 Mn |
| Mar 31, 2024 | 59.29 Mn |
| Dec 31, 2023 | 59.32 Mn |
| Sep 30, 2023 | 4.83 Mn |
| Jun 30, 2023 | 4.77 Mn |
| Mar 31, 2023 | 4.74 Mn |
| Dec 31, 2022 | 35.10 Mn |
| Sep 30, 2022 | 773,000.00 |
| Jun 30, 2022 | 2.07 Mn |
| Mar 31, 2022 | 3.57 Mn |
| Dec 31, 2021 | 4.19 Mn |
| Sep 30, 2021 | 4.57 Mn |
| Jun 30, 2021 | 4.96 Mn |
| Mar 31, 2021 | 2.56 Mn |
| Dec 31, 2020 | 5.34 Mn |
| Sep 30, 2020 | 3.83 Mn |
| Jun 30, 2020 | 2.34 Mn |
| Mar 31, 2020 | 2.29 Mn |
| Dec 31, 2019 | 2.49 Mn |
| Sep 30, 2019 | 2.65 Mn |
| Jun 30, 2019 | 2.82 Mn |
| Mar 31, 2019 | 2.87 Mn |
| Dec 31, 2018 | 929,000.00 |
| Sep 30, 2018 | 607,000.00 |
| Jun 30, 2018 | 565,000.00 |
| Mar 31, 2018 | 453,000.00 |
| Dec 31, 2017 | 404,000.00 |
| Sep 30, 2017 | 315,000.00 |
| Jun 30, 2017 | 358,000.00 |
| Mar 31, 2017 | 524,000.00 |
| Dec 31, 2016 | 569,000.00 |
| Sep 30, 2016 | 841,000.00 |
| Jun 30, 2016 | 928,000.00 |
| Mar 31, 2016 | 807,000.00 |
| Dec 31, 2015 | 823,000.00 |
| Sep 30, 2015 | 1.66 Mn |
| Jun 30, 2015 | 983,000.00 |
| Mar 31, 2015 | 1.90 Mn |
| Dec 31, 2014 | 911,000.00 |
| Sep 30, 2014 | 17.13 Mn |
| Jun 30, 2014 | 25.77 Mn |
| Mar 31, 2014 | 35.63 Mn |
| Dec 31, 2013 | 52.27 Mn |
| Sep 30, 2013 | 59.26 Mn |
| Jun 30, 2013 | 64.97 Mn |
| Mar 31, 2013 | 67.12 Mn |
| Dec 31, 2012 | 61.84 Mn |
| Sep 30, 2012 | 55.40 Mn |
| Jun 30, 2012 | 53.45 Mn |
| Mar 31, 2012 | 51.76 Mn |
| Dec 31, 2011 | 59.91 Mn |
| Sep 30, 2011 | 62.93 Mn |
| Jun 30, 2011 | 62.99 Mn |
| Dec 31, 2010 | 44.71 Mn |